Navigation Links
Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2014 On October 31, 2013
Date:10/28/2013

BOULDER, Colo., Oct. 28, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2014 and hold a conference call to discuss those results on Thursday, October 31, 2013.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Conference Call InformationDate: Thursday, October 31, 2013Time: 9:00 a.m. eastern timeToll-Free: (877) 261-8990Toll: (847) 619-6441Pass Code: 35902809Webcast, including Replay and Conference Call Slides:
http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began Phase 3 trials evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and in patients with BRAF-mutant melanoma in October 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and began a Phase 3 trial in patients with non-small cell lung cancer in October 2013.  Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.  For more information on Array, please go to www.arraybiopharma.com.CONTACT: Tricia Haugeto Array BioPharma Inc.(303) 386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arrayit Corporation Announces New Corporate Headquarters in Sunnyvale California
2. ARRAYit Corporation Receives $104,000 Purchase Order from the University of California
3. ARRAYit Corporation Ships Proprietary Life Sciences Products to Google Inc.
4. ARRAYit Corporation Ships Proprietary Life Sciences Products to Illumina Inc.
5. Gentris Corporation Launches Next Generation Human Transcriptome Array
6. Genentech Purchases Arrayit Technology
7. Arrayit on Major Fundraising Drive
8. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
9. Sequenom And CombiMatrix Announce Collaboration Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing
10. Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013
11. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... This week the The Voss Law Firm celebrates ... Bill Voss, the firm grew quickly and has built a reputation for excellence, trust, ... get the money they deserve from their insurance companies. , The Voss Law ...
(Date:8/23/2017)... DC (PRWEB) , ... August 23, 2017 , ... ... Oxygen Therapy continues to prove the safety and efficacy of HBOT in treating ... clinics across the US, points to research showing the similarities of the wounds ...
(Date:8/23/2017)... ... August 23, 2017 , ... PreCheck, Inc., ... 2017 Inc. 5000 with a three-year sales growth of 49 percent . ... and comprises the most comprehensive look at America’s independent entrepreneurs. This represents PreCheck’s ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
(Date:8/23/2017)... ... August 23, 2017 , ... A new literature review ... , points out that therapeutic modalities (physical therapy) is an important part of ... report, a wider scope of physical therapy options is showing promising results and ...
Breaking Medicine News(10 mins):